Seventeen in Crohn's disease: Less prime than we thought?

Gut

Volumn 61, Issue 12, 2012, Pages 1653-1654

  Raine, Tim ^a   Kaser, Arthur ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY P40; BRIAKINUMAB; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; PLACEBO; SECUKINUMAB; UNCLASSIFIED DRUG; USTEKINUMAB;

BAYES THEOREM; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; GENE OVEREXPRESSION; GENETIC RISK; HAPLOTYPE; HUMAN; IMMUNOLOGY; INFLAMMATION; MYCOSIS; NONHUMAN; NOTE; PATHOGENICITY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; TH17 CELL; TREATMENT FAILURE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; MALE;

EID: 84868689685     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302525     Document Type: Note

References (14)

1. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012. Published Online First: 17 May 2012 doi:10.1136/gutjnl-2011-301668
2. Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodiuminduced colitis in mice. Clin Immunol 2004;110:55-62. (Pubitemid 38177420)
3. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310-16.
4. Yang XO, Chang SH, Park H, et al . Regulation of inflammatory responses by IL-17F. J Exp Med 2008; 205:1063-75. (Pubitemid 351679682)
5. Ghoreschi K, Laurence A, Yang XP, et al. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011;32 :395-401.
6. Buonocore S, Ahern PP, Uhlig HH, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010;464:1371-5.
7. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin- 17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
8. Cotsapas C, Voight BF, Rossin E, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet 2011;7:e1002254.
9. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity 2011;35:857-69.
10. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
11. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362 :118-28.
12. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin- 12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79. (Pubitemid 39482500)
13. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135 :1130-41.
14. Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336 :489-93.